ArticleBlood2016

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Anita Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.